Related Experiment Video
Updated: May 28, 2026

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
Published on: December 27, 2013
Retargeted clostridial neurotoxins as novel agents for treating chronic diseases
Felix L Yeh1, Yiming Zhu, William H Tepp
1Department of Neuroscience, Howard Hughes Medical Institute, University of Wisconsin, Madison, Wisconsin 53706-1510, United States.
Abstract:
Botulinum neurotoxin (BoNT) A and B are used to treat neuropathic disorders; if retargeted, these agents could be used to treat medical conditions that involve secretion from nonneuronal cells. Here, we report novel strategies for successfully retargeting BoNTs, and also tetanus neurotoxin (TeNT), to primary human blood monocyte-derived macrophages where BoNT/B inhibited the release of tumor necrosis factor-α, a cytokine that plays a key role in inflammation. Furthermore, mice treated with retargeted BoNT/B exhibited a significant reduction in macrophage (MΦ) recruitment, indicating that these toxins can be used to treat chronic inflammation.
Related Concept Videos
Botulism
Microorganisms in Medicine and Therapeutics
Bacterial Toxins
Anthelminthic Agents
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

